文献速递系统性红斑狼疮

系统性红斑狼疮患者中羟氯喹和氯喹视网膜病变新危险因素的识别

Identification of new risk factors for hydroxychloroquine and chloroquine retinopathy in systemic lupus erythematosus patients.
PubMed 文献 · Semin Arthritis Rheum · 2024-02-12

这项病例对照研究(1:2)比较了48例出现羟氯喹或氯喹视网膜病变的系统性红斑狼疮患者与96例无病变对照,匹配性别、用药时长和诊断时年龄。多变量分析显示,合用SSRI/SNRI、抗磷脂综合征、血[HCQ]/[DCQ]比值<7.2和皮肤光型≥4与视网膜病变独立相关,而日剂量、血[HCQ]浓度和体重指数未显示关联。

要点

  • 合用SSRI/SNRI、抗磷脂综合征、血[HCQ]/[DCQ]比值<7.2和皮肤光型≥4是新的独立危险因素。
  • 日羟氯喹剂量、血[HCQ]浓度和体重指数未显示与视网膜病变独立相关。
  • 血[HCQ]/[DCQ]比值<7.2的OR为8.4(95%CI 2.7-30.8),皮肤光型≥4的OR为5.5(95%CI 1.4-26.5)。

核心结论

  • 该病例对照研究识别出血[HCQ]/[DCQ]比值、合用SSRI/SNRI、皮肤光型≥4和抗磷脂综合征为羟氯喹或氯喹视网膜病变的新危险因素。

研究设计与样本

  • 病例对照研究(1:2),纳入48例出现羟氯喹或氯喹视网膜病变的系统性红斑狼疮患者为病例,96例无视网膜病变的系统性红斑狼疮患者为对照。
  • 对照按性别、羟氯喹和/或氯喹治疗时长(±1年)及系统性红斑狼疮诊断时年龄(±5岁)匹配。

主要发现

  • 合用SSRI或SNRI与视网膜病变独立相关(OR 6.6,95%CI 1.2-40.9,p<0.01)。
  • 抗磷脂综合征与视网膜病变独立相关(OR 8.9,95%CI 2.2-41.4,p<0.01)。
  • 血[HCQ]/[DCQ]比值<7.2与视网膜病变独立相关(OR 8.4,95%CI 2.7-30.8,p<0.01)。
  • 皮肤光型≥4与视网膜病变独立相关(OR 5.5,95%CI 1.4-26.5,p=0.02)。
  • 日羟氯喹剂量、血[HCQ]浓度和体重指数未显示与视网膜病变独立相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term hydroxychloroquine (HCQ) or chloroquine (CQ) intake causes retinal toxicity in 0.3-8 % of patients with rheumatic diseases. Numerous risk factors have been described, eg, daily dose by weight, treatment duration, chronic kidney disease, concurrent tamoxifen therapy and pre-existing retinal or macular disease. However, those factors cannot explain the entire risk of developing antimalarial retinopathy. OBJECTIVE: This study was undertaken to identify new risk factors associated with HCQ or CQ retinopathy (QRNP) in systemic lupus erythematosus (SLE) patients. METHODS: This case-control (1:2) study compared SLE patients with QRNP (cases) to those without (controls). Controls were matched for sex and known QRNP risk factors: HCQ and/or CQ treatment duration (±1 year) and age (±5 year) at SLE diagnosis. RESULTS: Forty-eight cases were compared to 96 SLE controls. Multivariable logistic-regression analysis retained the following as independent determinants significantly associated with QRNP: concomitant selective serotonin-reuptake inhibitor (SSRI) or serotonin- and norepinephrine-reuptake inhibitor (SNRI) intake (OR [95 % confidence interval] 6.6 [1.2 to 40.9]; p < 0.01); antiphospholipid syndrome (OR=8.9 [2.2 to 41.4] p < 0.01); blood hydroxychloroquine/desethylchloroquine concentration ([HCQ]/[DCQ]) ratio <7.2 (OR 8.4 [2.7 to 30.8]; p < 0.01) or skin phototype ≥4 (OR 5.5 [1.4 to 26.5]; p = 0.02), but not daily HCQ dose, blood [HCQ] or body mass index. CONCLUSION: The results of this case-control study identified blood [HCQ]/[DCQ] ratio, concurrent SSRI/SNRI therapy, skin phototype ≥4 and antiphospholipid syndrome as new risk factors for QRNP.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Trefond L, Lhote R, Mathian A, et al. Identification of new risk factors for hydroxychloroquine and chloroquine retinopathy in systemic lupus erythematosus patients. Semin Arthritis Rheum. 2024. PMID: 38394986. doi:10.1016/j.semarthrit.2024.152417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。